Repository logo
 

IL-1α cleavage by inflammatory caspases of the noncanonical inflammasome controls the senescence-associated secretory phenotype.

Accepted version
Peer-reviewed

Change log

Authors

Wiggins, Kimberley A 
Parry, Aled J 
Cassidy, Liam D 
Humphry, Melanie 
Webster, Steve J 

Abstract

Interleukin-1 alpha (IL-1α) is a powerful cytokine that modulates immunity, and requires canonical cleavage by calpain for full activity. Mature IL-1α is produced after inflammasome activation and during cell senescence, but the protease cleaving IL-1α in these contexts is unknown. We show IL-1α is activated by caspase-5 or caspase-11 cleavage at a conserved site. Caspase-5 drives cleaved IL-1α release after human macrophage inflammasome activation, while IL-1α secretion from murine macrophages only requires caspase-11, with IL-1β release needing caspase-11 and caspase-1. Importantly, senescent human cells require caspase-5 for the IL-1α-dependent senescence-associated secretory phenotype (SASP) in vitro, while senescent mouse hepatocytes need caspase-11 for the SASP-driven immune surveillance of senescent cells in vivo. Together, we identify IL-1α as a novel substrate of noncanonical inflammatory caspases and finally provide a mechanism for how IL-1α is activated during senescence. Thus, targeting caspase-5 may reduce inflammation and limit the deleterious effects of accumulated senescent cells during disease and Aging.

Description

Keywords

IL-1, IL-1 alpha, caspase, inflammasome, inflammation, senescence, senescence-associated secretory phenotype, Animals, Caspases, Cells, Cultured, Cellular Senescence, Female, HeLa Cells, Humans, Inflammasomes, Inflammation, Interleukin-1alpha, Mice, Mice, Inbred C57BL

Journal Title

Aging Cell

Conference Name

Journal ISSN

1474-9718
1474-9726

Volume Title

18

Publisher

Wiley
Sponsorship
British Heart Foundation (None)
British Heart Foundation (None)
British Heart Foundation (RG/16/8/32388)
British Heart Foundation (FS/18/19/33371)
Medical Research Council (MR/M013049/1)
Cancer Research UK (C14303/A17197)
Medical Research Council (MR/R010013/1)
Medical Research Council (MR/M020134/1)
British Heart Foundation (FS/18/19/33371)
Work was funded by British Heart Foundation grants FS/13/3/30038, FS/18/19/33371 and RG/16/8/32388 (MC); Cancer Research UK Cambridge Institute Core Grant C14303/A17197, Medical Research Council grants MR/M013049/1 and MR/R010013/1 (MN); and the Cambridge NIHR Biomedical Research Centre.